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Abstract  
Background: Re-emergence of pertussis has been reported in Iran despite a 
high rate of vaccination coverage. Low efficacy of the vaccine might be due 
to the genetic divergence between clinical versus vaccine strains. In the current 
study, the genetic profiles of clinical isolates and vaccine strains of Bordetella 
pertussis (B. pertussis) were assessed by using Pulsed Field Gel Electrophoresis 
(PFGE). 
Methods: Following phenotypic and molecular identification of isolates, XbaI-
digested genomic DNA of 5 clinical isolates, 2 vaccine strains and a Tohama I 
strain were analyzed by PFGE along with B. parapertussis as a control. 
Results: Seven distinct PFGE profiles were found among all examined iso-
lates/strains. In 5 clinical isolates, 4 profiles were identified whereas the vaccine 
strains displayed 2 distinct profiles. The reference strain, Tohama I had a dis-
tinct profile. Vaccine and clinical profiles had low similarity, with relatedness of 
approximately 40%.  
Conclusion: The genetic profiles of B. pertussis were different between circulat-
ing isolates and vaccine strains used in the national vaccination programs. 
Since new genetic profiles of B. pertussis can be disseminated periodically, the 
profiles of isolates circulating in the population should be monitored over the 
course of the re-emergence.  
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Introduction 
 
Bordetella pertussis is a strict human path-
ogen causing severe contagious respiratory 
infection, whooping cough or pertussis 1. Per-
tussis remains one of the ten leading causes of 
 
 
 
death from infectious diseases among children 
2. The development of whole-cell pertussis 
(wP) vaccines since 1950s, and the broad use 
of this vaccine has greatly reduced the inci-
Avicenna J Med Biotech 2014; 6(3): 178-184 
* Corresponding authors: 
Fazel Shokri, Ph.D.,  
Monoclonal Antibody Research 
Center, Avicenna Research 
Institute, ACECR, Tehran, Iran  
Masoumeh Douraghi, Ph.D., 
Division of Microbiology,  
Department of Pathobiology, 
School of Public Health,  
Tehran University of Medical 
Sciences, Tehran, Iran 
Tel: +98 21 22432020, 42933152 
Fax: +98 21 22432021, 88954913 
E-mail:   
fshokri@tums.ac.ir,  
mdouraghi@tums.ac.ir 
Received: 25 Dec 2013 
Accepted: 15 Feb 2014 
Haghighi F, et al 
Avicenna Journal of Medical Biotechnology, Vol. 6, No. 3, July-September 2014  179
dence of pertussis in developed and develop-
ing countries. Despite the Expanded Program 
of Immunization (EPI), pertussis has not been 
eradicated and the re-emergence of the dis-
ease is reported worldwide 3. Re-emergence 
of pertussis is attributed to several factors 
such as waning of vaccine-induced immunity, 
pathogen adaptation, antigenic divergence be-
tween vaccine strains and circulating clinical 
isolates, and the resurgence of new variants of           
B. pertussis 4-6. 
According to the World Health Organiza-
tion (WHO) reports, the diphtheria toxoid, te-
tanus toxoid and pertussis (DTP) vaccine 
coverage is estimated to be greater than 96% 
in Iran since the year 2000 7. However, the 
pertussis cases increased from 464 in 2010 to 
650 in 2011 and the national vaccination pro-
grams had a limited impact on the incidence 
of pertussis in various districts of the country 
in recent years 8. One study in assessment of 
the immune response against B. pertussis in 
Iranian children showed that half of the vac-
cinated children aged 8 months to 6 years did 
not display protective antibody levels to per-
tussis antigens 9. Evaluation of the immuno-
genicity of Diphtheria, Tetanus and whole-
cell Pertussis (DTwP) vaccine used in Iran also 
demonstrated lower immunogenicity against 
pertussis compared to diphtheria and tetanus 
10. Moreover, the majority of reported pertus-
sis cases in 2009-2010 were children vac-
cinated by DTwP 11.  
Since one reason for low efficacy of the 
vaccine might be the genetic divergence be-
tween vaccine and clinical strains, studies 
should be designed to characterize the ge-
nomic pattern of the circulating isolates and 
vaccine strains of B. pertussis. The aim of this 
study was to determine the genetic profiles of 
clinical isolates and vaccine strains of B. per-
tussis using a golden standard typing method 
with high discriminatory power, PFGE. 
Materials and Methods 
 
Isolates/strains and growth condition 
A total of 11 suspected clinical isolates of                
B. pertussis named Bp1-11 (Pertussis Refer-
ence Laboratory, Pasteur Institute of Iran, 
Tehran, Iran), Tohama I (ATCC® BAA-589™) 
as reference strain, and 2 vaccine strains (De-
partment of Aerobic Bacterial Vaccines, Razi 
Vaccine and Serum Research Institute) were 
studied. B. parapertussis (ATCC:15311) was 
included as a control. Two vaccine strains 
used in this study were Bp509, and Bp134. 
These two strains have been used for produc-
tion of DTwP vaccine in Iran. Two subcul-
tures of Bp509 strain, including Bp509/1997 
and Bp509/2000 were available. These iso-
lates were prepared and frozen in 1997 and 
2000 from the original stock of Bp509. Fro-
zen bacteria were cultured onto Bordet-Gen-
gou Agar (BGA) (Becton Dickinson, USA) 
supplemented with 1% glycerol, peptone, and 
20% defibrinated sheep blood and were incu-
bated at 35°C for 72 hr. 
 
Phenotypic identification 
Colonies were identified as B. pertussis by 
a combination of colony morphology, growth 
rate, Gram stain, and biochemical tests such 
as oxidase, catalase, urease, nitrate reductase, 
and lack of growth on the MacConkey and 
blood agar 12. 
 
Molecular identification  
Genomic DNA extraction was performed 
using the standard phenol-chloroform extrac-
tion method 13. Specific primers targeting in-
sertion sequence 481 (IS481) and pertussis 
toxin promoter (ptxP) were used to amplify 
181 base pair (bp) and 573 bp products 14,15, 
respectively (Table 1). Amplification of IS481 
region was carried out in a total reaction vol-
ume of 20 μl containing 2 μl 10× PCR buffer 
(CinnaGen co., Iran), 1.5 mM MgCl2 (Cinna- 
Gen co., Iran), 0.2 mM deoxynucleotide (Cinna-
Table 1. Specific primers sequences targeting IS481 and ptxP 
 
Target region Primer sequence (5′-3′) Amplicon size (bp) Reference 
IS481 5′-GATTCAATAGGTTGTATGCATGGTT-3′ 5′-TTCAGGCACACAAACTTGATG-3′ 181 14 
ptxP 5′-AATCGTCCTGCTCAACCGCC-3′ 5′-GGTATACGGTGGCGGGAGGA-3′ 573 15 
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Gen co., Iran), 0.25 mM of each primer (Bio-
neer, Seoul, South Korea ), 0.5 U Taq poly-
merase (CinnaGen co., Iran), and 10 ng DNA. 
The Thermocycler (Peqlab, Germany) was set 
with the following conditions: Initial denatur-
ation for 5 min at 95 °C and 30 cycles includ-
ing denaturation for 30 s at 95°C, annealing 
for 30 s at 54°C, extension for 2 min at 72°C, 
and final extension for 10 min at 72°C. For 
amplification of ptxP, in a total volume of  
25 μl, the same reaction mix was used as de-
scribed above, with the exceptions that Taq 
polymerase was increased to 1 U, 10% of di-
methyl sulfoxide (CinnaGen co., Iran) was 
added, and annealing temperature was in-
creased to 58°C. Electrophoresis was per-
formed in a 1% agarose (Invitrogen, USA) gel 
and was stained with 0.5 μg/ml ethidium bro-
mide (Sigma, USA). 
 
Pulsed field gel electrophoresis (PFGE)   
A single colony of each clinical isolate and 
vaccine strain confirmed as B. pertussis were 
subcultured onto BGA. The bacterial suspen-
sion was prepared in Cell Suspension Buffer 
(CSB) containing 100 mM Tris-HCl (Merck, 
Germany) and 100 mM EDTA (Promega, 
UK) with an optical density of 0.5 at 650 nm. 
Each plug was prepared by adding 120 μl of 
bacterial suspension and 20 μl of 50 mg/ml 
proteinase K (Sigma, USA) to 120 μl of 1% 
Seakem Gold agarose (FMC BioProducts, Rock 
land, ME) and was incubated in lysis buffer 
[100 mM Tris-HCl, 100 mM EDTA, 1% lau-
royl sarcosine (Sigma, USA), and 0.5 mg/ml 
solution of proteinase K (Sigma, USA)] at 
55°C overnight. The plugs were washed with 
deionized water and 1× TE (10 mM Tris-HCl, 
1 mM EDTA). The plug slices were incubated 
with 30 U of XbaI (Fermentas, Lithuania) at 
37°C for 16 hr. PFGE was performed with 
1% agarose gel in a contour-clamped homo-
geneous electric field (CHEF-DRIII) (Bio-
Rad, USA) apparatus at 6 V/cm with a 120°C 
angle for 23 hr at 12°C with initial switch 
time of 2.2 s and the final switch of 55 s. The 
genomic DNA of Salmonella enterica sero-
type Braenderup H9812 was used as the size 
marker. The obtained XbaI PFGE profiles 
were analyzed using GelComparII version 4 
(Applied Maths, Sint-Martens-Latem, Bel-
gium). The Unweighted Pair Group Method 
with arithmetic mean Algorithm (UPGMA) 
was used as the clustering method, with a 1% 
band tolerance, 1% optimization, and the 
Dice’s coefficient 16. The band pattern of each 
strain was confirmed visually. Isolates with a 
DNA band pattern differing by ≥1 band were 
defined as single type or distinct PFGE pro-
file. 
 
Results 
Isolates as small, smooth, gray colonies 
which appeared at a minimum of 72 hr on 
BGA were identified as B. pertussis and they 
were stained as Gram negative coccobacilli. 
B. pertussis colonies did not grow on com-
mon laboratory media such as MacConkey 
agar and blood agar and were distinguished 
from other Bordetella species by oxidase- and 
catalase-positive but urease- and nitrate-nega-
tive reactions. As indicated in table 2, five of 
11 suspected clinical isolates and all vaccine 
strains as well as Tohama I were verified as 
B. pertussis based on phenotypic and bio-
chemical characteristics. 
Five of the 11 clinical isolates and all vac-
cine strains yielded 181 bp (Figure 1) and 573 
bp (Figure 2) amplicons through amplification 
of IS481 and ptxP, respectively, confirming 
the identity of B. pertussis. A total of 5 clini-
cal isolates, 2 vaccine strains, and Tohama I 
strain were firmly confirmed via both pheno-
typic and molecular methods. Chromosomal 
Figure 1. The IS481 amplification using specific primers 
yielded a product of 181 bp typical to clinical isolates and 
vaccine strains of B. pertussis. L: 100 bp ladder (Fermentas, 
Lithuania); 1: Tohama I strain as reference strain; 2-6: clini-
cal isolates of B. pertussis; 7-9: vaccine strains of B. pertus-
sis; 10-15: non-B. pertussis clinical isolates; 16: B.  paraper-
tussis; 17: Negative control (distilled water) 
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DNA of these confirmed strains were typed 
using PFGE. Seven distinct PFGE profiles 
were found among all examined strains. In the 
5 clinical isolates, 4 profiles were identified 
and named C1 to C4. Two clinical isolates 
with the same number as well as same pro-
files for bands size were grouped in common 
type 1 (CT1). The other clinical isolates (Bp3, 
Bp5, and Bp9) had 80% of similarity, there-
fore belonged to three different types, named 
single type 3, 1, and 2 (ST3, ST1, and ST2), 
respectively. The 2 vaccine strains displayed 
2 distinct profiles and were named V1 and 
V2. Two vaccine isolates which were derived 
from the Netherlands strain Bp509 had exact-
ly the same profile and were grouped in CT2. 
The vaccine strain, Bp134, had unique PFGE 
profile and was defined as ST5. As shown in 
figure 3, Tohama I strain was included in 
dendrogram as a reference strain (R1) with 
unique profile and was considered as ST4. 
Vaccine profiles and clinical profiles had low 
similarity, with relatedness of approximately 
40%. B. parapertussis which was used as a 
control had distinct PFGE profile with low 
relatedness (<40%) to all typed B. pertussis 
isolates/strains. 
 
Discussion 
 
In this study, the genetic profiles of a lim-
ited number of B. pertussis isolates recovered 
from Iranian patients were analyzed and com-
pared with the two strains which were used 
for production of the national whole-cell per-
tussis vaccine. PFGE as a typing method was 
used and different PFGE patterns among the 
clinical isolates were found. This finding in-
dicated that different B. pertussis isolates 
were circulating despite high vaccination cov-
Table 2. Differential characteristics of vaccine strains, clinical isolates, and reference strains of B. pertussis and B. parapertussis 
 
Strain/Isolate 
Characteristic 
Bp509/ 
1997 
Bp509/ 
2000 
Bp 
134 
Tohama 
I 
B. 
parapertussis Bp1 Bp2 Bp3 Bp4 Bp5 Bp6 Bp7 Bp8 Bp9 
Bp 
10 
Bp 
11 
Growth rate* (Days) 4 4 4 4 1 1 1 4 1 5 1 5 5 5 1 1 
Catalase + + + + + + + + + + + + + + + + 
Oxidase + + + + - + + + + + + + + + + + 
Nitrate reductase - - - - - + - - - - - - - - - - 
Urease - - - - + - + - + - + - - - + + 
Growth on                 
     Blood agar - - - - + - + - - - - - - - - - 
     MacConkey agar - - - - V - + - - - - - - - - - 
 
* Growth rate represents minimum days of appearance of colonies on BGA; Bp: Bordetella pertussis, V: Variable growth patterns 
 
Figure 2. The ptxP amplification using specific primers 
yielded a product of 573 bp typical to clinical isolates and 
vaccine strains of B. pertussis. L: 100 bp ladder (Fermentas, 
Lithuania); 1: Tohama I strain as reference strain; 2-6: clini-
cal isolates of B. pertussis; 7-9: vaccine strains of B. pertus-
sis; 10-15: non-B. pertussis clinical isolates; 16: B. paraper-
tussis; 17: negative control (distilled water) 
Figure 3. Genomic analysis of B. pertussis using PFGE. The 
dendrogram shows PFGE profiles of clinical isolates (C), 
vaccine strains (V), and reference strain Tohama I (R1). 
B. parapertussis (Bpp) was used as a control. The PFGE 
clusters are indicated as common type (CT) or single type 
(ST) 
١٨
Iranian Bordetella pertussis PFGE Profiles 
Avicenna Journal of Medical Biotechnology, Vol. 6, No. 3, July-September 2014       182 
erage in Iran. However, low heterogeneity has 
been found among the clinical isolates and 
these isolates belonged to different profiles 
with an approximately 80% of genetic relat-
edness. Therefore, the results were consistent 
with previous studies that classified B. pertus-
sis as a genetically monomorphic pathogen 
17,18.  
Two strains containing the same PFGE pat-
tern were also identified among clinical iso-
lates. They were more likely to be related and 
to have a common source. Two PFGE pat-
terns among the vaccine strains were ob-
served in this study. These 2 profiles belong-
ed to strains used in vaccine production in 
Iran. Two isolates included in V1 profile were 
subcultures or derivatives of a vaccine strain 
of the Netherlands origin, Bp509, which were 
cultured at different time intervals. The exact-
ly similar PFGE patterns of our vaccine 
strains suggest that repeated subculture did 
not lead to genetic divergence over time, as 
previously described by Advani et al 19. How-
ever, two studies showed that the PFGE pro-
files changed upon repeated subculture 20,21. 
The XbaI digested DNA of the reference 
strain (Tohama I) had PFGE profile exactly 
similar to profile obtained by others who clus-
tered Tohama I in PFGE group II 22. The 
DNA of vaccine strains Bp509 and Bp134 
were also digested with XbaI and the profiles 
were comparable with that of other studies. 
The strain Bp509 showed exactly similar pro-
file same as several other studies 23-25, but a 
controversy was found in just one study in 
which Bp509 and Bp134 were considered the 
same 23. In this study, strain Bp134 showed 
the same profile as reported in previous stud-
ies 26,27, but Bottero et al reported similar pro-
files for Bp509 and Bp134 in their dendro-
gram 23. This controversy may be due to an 
error in processing the stocks of bacteria or 
interpretation of the dendrogram.  
Comparison of the genetic profiles of vac-
cine strains and clinical isolates demonstrated 
that vaccine strains had different PFGE pat-
terns and were not matched to circulating iso-
lates. One explanation for this variation might 
be associated to the low efficacy of currently 
used vaccine which may lead to adaptation of 
the pathogen and selection of new variants of 
B. pertussis 5. Another explanation is that the 
circulating bacteria may evade the host re-
sponses and in turn evolve efficient mecha-
nisms to overcome the vaccine-induced im-
munity 28,29. It is also possible that such gross 
genetic variations might not be clinically rel-
evant and reflect random mutations intro-
duced in the genome of Bp isolates obtained 
from the patients. However, more detailed 
genetic and structural investigations are re-
quired to address this issue.  
Several studies have compared the PFGE 
profiles of clinical isolates and vaccine strains 
of B. pertussis in different countries. The ma-
jority of these studies have indicated that non-
vaccine isolates were recovered from patients 
with pertussis disease and these isolates were 
genetically different from the vaccine strains 
19,22,30. However, in the study of Elomaa et al, 
the profile of one of the two assessed vaccine 
strains was detected among the circulating 
isolates 31. 
 
Conclusion 
 
It was demonstrated that non-vaccine iso-
lates of B. pertussis were different from vac-
cine strains used in the national vaccination 
program. Since new genetic profiles of B. per-
tussis can be disseminated periodically, the 
profiles of isolates circulating in the popula-
tion should be monitored over the course of 
the re-emergence. PFGE is used as a golden 
standard method for determining the gross 
polymorphisms within restriction enzyme Re-
cognition Sites (RS) in whole genome and for 
identifying the extensive rearrangements, de-
letions, and insertions that affect the restric-
tion fragment profile 32. However, some ge-
netic variations such as single nucleotide pol-
ymorphism, short tandem repeat polymor-
phism, non-RS repetitive sequence polymor-
phisms, and mutations changing the genetic 
code could not be assessed via PFGE. There-
fore, sequencing based methods need to be 
used to characterize and interpret such minute 
Haghighi F, et al 
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and small-scale changes. Further monitoring 
may provide more information about the 
strains or antigens needed for development of 
more effective vaccines. 
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